Weight Loss Drug Benefits
-
{
- All
- News
- Videos
-
GLP-1 Drugs May Trigger Muscle Loss In Cirrhosis Patients: Study
GLP-1 drugs are often praised for their metabolic benefits, including improved blood sugar control and weight reduction. However, in patients with liver cirrhosis, these benefits may come with trade-offs.
-
Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss
This innovative compound is known as a 'quintuple agonist' because it combines the power of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists with lanifibranor.
-
Fake Mounjaro Worth Rs 56 Lakh Seized In Gurugram: What It Can Do To Your Body
Fake Mounjaro injections seized in Gurugram highlight rising counterfeit weight-loss drug risks and severe health dangers.
-
On Ozempic Or Wegovy? Doctors Say Stop Before Surgery, Here's Why
The ASA guidance suggests that patients on GLP-1 drugs should consult their healthcare providers well in advance of any planned surgery.
-
Ozempic Might Preserve Lean Body Mass Better Than Mounjaro: Study
Both tirzepatide and semaglutide belong to a class of drugs that mimic hormones involved in appetite regulation. Semaglutide works by mimicking GLP-1, a hormone that helps control hunger and blood sugar levels.
-
Natural Ozempic, No Side Effects: Stanford Scientists Discover Peptide That Can Rival The GLP-1 Drug
One of the most fascinating aspects of this discovery is the role of artificial intelligence. Researchers developed a tool called "Peptide Predictor" to scan all human protein-coding genes.
-
Struggling To Lose Weight On Ozempic, Mounjaro? Study Says Your Genes Might Be the Hurdle
A new study reveals that your genes could be the hidden hurdle, explaining the differences in how bodies respond to weight loss drugs.
-
"Weight-Loss Injections Are Not For Wedding Prep Shortcut", Doctors Warn Against Misuse Of Ozempic, Mounjaro
These medications are designed for people with obesity or related health conditions, not for short-term aesthetic goals. When used by otherwise healthy individuals aiming for quick slimming, the balance between benefit and risk often becomes unfavour
-
Semaglutide Weight-Loss Drugs May Help Prevent Deadly Heart Attack Complications
Popular weight-loss drugs like semaglutide may reduce life-threatening complications after heart attacks, a UK study finds. By improving blood flow in tiny vessels, these drugs could help the heart recover, but human trials are still needed.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Heart Benefits Fade After You Stop Taking GLP-1 Drugs: Study
This study, published in BMJ Medicine, investigated what happens when people with Type 2 diabetes stop or interrupt their treatment with GLP-1 drugs.
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
GLP-1 Drugs May Trigger Muscle Loss In Cirrhosis Patients: Study
GLP-1 drugs are often praised for their metabolic benefits, including improved blood sugar control and weight reduction. However, in patients with liver cirrhosis, these benefits may come with trade-offs.
-
Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss
This innovative compound is known as a 'quintuple agonist' because it combines the power of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists with lanifibranor.
-
Fake Mounjaro Worth Rs 56 Lakh Seized In Gurugram: What It Can Do To Your Body
Fake Mounjaro injections seized in Gurugram highlight rising counterfeit weight-loss drug risks and severe health dangers.
-
On Ozempic Or Wegovy? Doctors Say Stop Before Surgery, Here's Why
The ASA guidance suggests that patients on GLP-1 drugs should consult their healthcare providers well in advance of any planned surgery.
-
Ozempic Might Preserve Lean Body Mass Better Than Mounjaro: Study
Both tirzepatide and semaglutide belong to a class of drugs that mimic hormones involved in appetite regulation. Semaglutide works by mimicking GLP-1, a hormone that helps control hunger and blood sugar levels.
-
Natural Ozempic, No Side Effects: Stanford Scientists Discover Peptide That Can Rival The GLP-1 Drug
One of the most fascinating aspects of this discovery is the role of artificial intelligence. Researchers developed a tool called "Peptide Predictor" to scan all human protein-coding genes.
-
Struggling To Lose Weight On Ozempic, Mounjaro? Study Says Your Genes Might Be the Hurdle
A new study reveals that your genes could be the hidden hurdle, explaining the differences in how bodies respond to weight loss drugs.
-
"Weight-Loss Injections Are Not For Wedding Prep Shortcut", Doctors Warn Against Misuse Of Ozempic, Mounjaro
These medications are designed for people with obesity or related health conditions, not for short-term aesthetic goals. When used by otherwise healthy individuals aiming for quick slimming, the balance between benefit and risk often becomes unfavour
-
Semaglutide Weight-Loss Drugs May Help Prevent Deadly Heart Attack Complications
Popular weight-loss drugs like semaglutide may reduce life-threatening complications after heart attacks, a UK study finds. By improving blood flow in tiny vessels, these drugs could help the heart recover, but human trials are still needed.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Heart Benefits Fade After You Stop Taking GLP-1 Drugs: Study
This study, published in BMJ Medicine, investigated what happens when people with Type 2 diabetes stop or interrupt their treatment with GLP-1 drugs.
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
